Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV)
· seekingalpha.com
Roivant Sciences outlook: LISRAYA approval strengthens revenue, while brepocitinib and mosliciguat could expand immunology/pulmonary franchises. Click for more on ROIV stock.
Roivant Sciences Ltd. ( ROIV ) is a clinical- and commercial-stage biopharmaceutical company. However, its business model focuses on creating shareholder value ...